NEW YORK, March 27 – Database and bioinformatics company GeneData said Tuesday it entered a multi-year collaboration to supply its Phylospher comparative genomics software for the study of pathogens to Novartis Pharma, extending a relationship between the two companies that began three years ago.
In February, GeneData announced that Novartis had licensed its Expressionist microarray data analysis system.
Under the terms of the agreement, GeneData will install its Phylosopher software throughout Novartis. The software system allows researchers to analyze the genomes of pathogens by comparing them with genomes of other organisms.
GeneData said its software is capable of characterizing genes, proteins, and pathways to lead to the development of new anti-microbial drugs as well as allowing researchers to study mechanisms-of-action, identifying pathogenic factors in specific species, and evaluating drug leads.
Financial terms were not disclosed.
Last week, GeneData said Japan’s National Institute of Technology and evaluation purchased the Phylospher software to help annotate genomes of various microbes, including two heat-resistant microbes it has already sequenced.